Clinical Trial Update: Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating monthly long-acting GA Depot injections (25 mg or 40 mg) for primary progressive multiple sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• Glatiramer acetate depot (GA Depot) (glatiramer acetate)

Snippet

Sponsor: Mapi Pharma Ltd. | Conditions: Primary Progressive Multiple Sclerosis | Phase 2 | Status: TERMINATED